All In Biotech

Drug Trial Radar · NCT07361874

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

IMPACT-MACS Study: Investigating the Mechanisms, Pathophysiology, and Cardiometabolic Treatment in Mild Autonomous Cortisol Secretion

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Mar 5, 2026

Primary completion

May 31, 2030

Study completion May 31, 2030

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life. The main questions the study aims to answer are: 1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS? 2. How do these treatments change cortisol patterns and other cardiometabolic risk factors? 3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS? 4. Among participants who enter the optional extension phase, are treatment-related changes maintained or further modified with longer-term treatment and follow-up? Participants will: 1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls 2. Complete clinic visits and phone visits 3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being 4. If eligible, have the option to participate in an extension phase with continued treatment and follow-up through approximately 12 months

Conditions

  • Mild Autonomous Cortisol Secretion (MACS)
  • Autonomous Cortisol Secretion (ACS)
  • Subclinical Cushing's
  • Mild Autonomous Cortisol Excess

Interventions

  • Intervention 1: AdrenalectomyProcedure

    Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up.

  • Intervention 2: SemaglutideDrug

    Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Insulin Sensitivity (M-value), mg/kg/minTime frame: Baseline to Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.